PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers

SIMPLE SUMMARY: OlympiAD and EMBRACA trials demonstrated the efficacy of PARPi, compared to chemotherapy, in patients with HER2-negative metastatic breast cancers (mBC) carrying a germline BRCA mutation. Patients with ER+/HER2-BRCA-mutated mBC seemed to have a higher risk of early disease progressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Collet, Laetitia, Péron, Julien, Penault-Llorca, Frédérique, Pujol, Pascal, Lopez, Jonathan, Freyer, Gilles, You, Benoît
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833594/
https://www.ncbi.nlm.nih.gov/pubmed/35158866
http://dx.doi.org/10.3390/cancers14030599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833594/
https://www.ncbi.nlm.nih.gov/pubmed/35158866
http://dx.doi.org/10.3390/cancers14030599

Ejemplares similares